#03 Carolina Oliveira, the founder & CEO of OneSkin Technologies | Skin Aging, OneSkin, and Building a Longevity Company
Live Longer World
00:00
Physitting
It's hard to measure that in vivo. In vitro, we have some models that we treat for 48 hours and then we see like 20, 30% decrease. So the more that I use, if you have the peptide, the peptide will help yourself to repair more damage. It's not going to clear 100% of senescent cells. And this definitely wouldn't be a safe cosmetic to bring to the market. We always need to be careful of bringing something that is efficient but also doesn't disrupt your tissue homeostasis.
Play episode from 20:24
Transcript
